Table 1.
Mouse strain, genotype, number, intervention and schedule used for WIHN trials.
| Experiment | Mouse Strain | # of Mice | Intervention | Day of Intervention | Day of CSLM Assessment |
|---|---|---|---|---|---|
| High vs Low Gene Expression-Early; High vs Low Gene Expression-Late | C57 vs. C57 x FVB x SJL C57 x FVB x SJL | 4 mice per strain; 3 mice/group | none | ----- | wound closure; ~WD20-24 |
| Standard WIHN vs Fringe Cuts | C57BL/6J | 14–15 mice/group | 10 cuts/side | WD0 | ~WD20-24 |
| Exogeneous Poly (I:C) addition | C57 x FVB x SJL; B6;129S1-Tlr3tm1Flv/J | 10–11 mice/group; 9 mice/group | 500ng Poly IC injected into wound | WD3 | ~WD20-24 |
| Rnase III addition | C57 x FVB x SJL | 17–19 mice/group | 15 units Rnase III injected into wound | WD3 | ~WD20-24 |
| WIHN in TLR3 KO | B6;129S1-Tlr3tm1Flv/J; B6;129SF2/J | 6 mice/group | none | ----- | ~WD20-24 |
| Exogeneous IL-6 addition | C57BL/6J B6N.129S1-Tlr3tm1Flv/J | 30 mice/group 8–10 mice/group | 25 ng rmIL-6 protein injected into wound 500ng rmIL-6 protein injected into wound | WD7 WD7 |
~WD20-24 |
| Importance of IL-6Rα | K14-ERT2-Cre x IL-6Ralphafl/fl (both C57BL/6) | 3–6 mice/group | I.P. tamoxifin every other day | WD5-WD14 | ~WD20-24 |
| Cucurbitacin I | C57 x FVB x SJL | 10–14 mice/group | 2mg/kg cucurbitacin I injected into wound | WD7 | ~WD20-24 |
| Importance of Stat3 in WIHN | K5-ERT2-Cre x Stat3 fl/fl (both C57BL/6) | 10–15 mice/group | I.P. tamoxifin every other day | WD0-WD14 | ~WD20-24 |
| Role of T- and B- cells | NOD.Cg- PrkdcscidIl2rgtm1Wjl (NOD/ShiLt) | 5 mice | none | ----- | ~WD20-24 |